Pages that link to "Q43877522"

The following pages link to Evaluation of bronchodilator responses in patients with "irreversible" emphysema (Q43877522):

Displaying 31 items.

• Dynamic lung hyperinflation and its clinical implication in COPD (Q33441638) (← links)
• Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: a cross sectional study (Q34403827) (← links)
• Comparison of spirometric changes in the response to bronchodilators of patients with asthma or chronic obstructive pulmonary disease (Q34599761) (← links)
• Medical management of chronic obstructive pulmonary disease (Q35610397) (← links)
• The confounding effects of thoracic gas compression on measurement of acute bronchodilator response (Q35855138) (← links)
• Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids (Q35876509) (← links)
• Performance enhancement in chronic obstructive pulmonary disease. (Q36309971) (← links)
• Outcome measures for COPD treatments: a critical evaluation (Q36602287) (← links)
• Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis (Q36695412) (← links)
• The clinical importance of dynamic lung hyperinflation in COPD. (Q36760103) (← links)
• A pilot study of inspiratory capacity and resting dyspnea correlations in exacerbations of COPD and asthma (Q37236604) (← links)
• New physiological insights into dyspnea and exercise intolerance in chronic obstructive pulmonary disease patients (Q38066983) (← links)
• Pharmacological management of breathlessness in COPD: recent advances and hopes for the future (Q38817813) (← links)
• Impact of bronchodilator use on the prevalence of COPD in population-based samples (Q39798721) (← links)
• Efficiency of neural respiratory drive for the assessment of bronchodilator responsiveness in patients with chronic obstructive pulmonary disease: an exploratory study (Q40556568) (← links)
• The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients (Q41908094) (← links)
• Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. (Q42776522) (← links)
• Bronchodilation in COPD: beyond FEV1-the effect of albuterol on resistive and reactive properties of the respiratory system. (Q45998472) (← links)
• Single dose of inhaled procaterol has a prolonged effect on exercise performance of patients with COPD. (Q46522568) (← links)
• The Link between Reduced Inspiratory Capacity and Exercise Intolerance in Chronic Obstructive Pulmonary Disease. (Q47923166) (← links)
• Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease. (Q53186884) (← links)
• Chronic Obstructive Pulmonary Disease: Quantification of Bronchodilator Effects by Using Hyperpolarized He MR Imaging (Q53409001) (← links)
• Evaluating bronchodilator effects in chronic obstructive pulmonary disease using diffusion-weighted hyperpolarized helium-3 magnetic resonance imaging (Q56775317) (← links)
• Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness tiotropium alone in COPD (Q64106611) (← links)
• Basic spirometry testing and interpretation for the primary care provider. (Q64922388) (← links)
• Debunking myths in pulmonary function testing. (Q65001779) (← links)
• Chronic obstructive pulmonary disease in women (Q79987730) (← links)
• [Which definition to use when defining reversibility of airway obstruction?] (Q80447701) (← links)
• [Evaluation and follow up of hyperinflation in COPD] (Q83781465) (← links)
• Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea (Q83828553) (← links)
• Forced expiratory volumes in 3 s is a sensitive clinical measure for assessment of bronchodilator reversibility in elderly Chinese with severe lung function impairment (Q93184812) (← links)